TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 718-727

  Azijn, Hilde ^a   Tirry, Ilse ^a   Vingerhoets, Johan ^a   De Béthune, Marie Pierre ^a   Kraus, Guenter ^a   Boven, Katia ^b   Jochmans, Dirk ^a   Van Craenenbroeck, Elke ^a   Picchio, Gaston ^b   Rimsky, Laurence T ^a  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLERIXAFOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SCREENING TEST; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE;

ANTI-HIV AGENTS; BENZOXAZINES; CELL LINE; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR STRUCTURE; NEVIRAPINE; NITRILES; PYRIDAZINES; PYRIMIDINES;

EID: 75749118495     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00986-09     Document Type: Article

References (52)

1. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M.-P. de Béthune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Antinori, A., M. Zaccarelli, A. Cingolani, F. Forbici, M. G. Rizzo, M. P. Trotta, S. Di Giambenedetto, P. Narciso, A. Ammassari, E. Girardi, A. De Luca, and C. F. Perno. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retroviruses 18:835-838.
3. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
4. Balotta, C., G. Facchi, M. Violin, S. Van Dooren, A. Cozzi-Lepri, F. Forbici, A. Bertoli, C. Riva, D. Senese, P. Caramello, G. Carnevale, G. Rizzardini, L. Cremonini, L. Monno, G. Rezza, C. F. Perno, G. Ippolito, A. d'Arminio-Monforte, A. M. Vandamme, and M. Moroni. 2001. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27:499-505.
5. Basavapathruni, A., J. Vingerhoets, M. P. de Béthune, R. Chung, C. M. Bailey, J. Kim, and K. S. Anderson. 2006. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 45:7334-7340.
6. Benjahad, A., M. Croisy, C. Monneret, E. Bisagni, D. Mabire, S. Coupa, A. Poncelet, I. Csoka, J. Guillemont, C. Meyer, K. Andries, R. Pauwels, M. P. de Béthune, D. M. Himmel, K. Das, E. Arnold, C. H. Nguyen, and D. S. Grierson. 2005. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)- ones: in vitro evaluation of new C-3-amino-subsituted and C-5,6-alkyl- substituted analogues against clinically important HIV mutant strains. J. Med. Chem. 48:1948-1964.
7. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
8. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
9. Brennan, T. M., D. L. Taylor, C. G. Bridges, J. P. Leyda, and A. S. Tyms. 1995. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res. 26:173-187.
10. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retroviruses 7:295-302.
11. Buckheit, R. W., Jr., J. L. Roberson, C. Lackman-Smith, J. R. Wyatt, T. A. Vickers, and D. J. Ecker. 1994. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10:1497-1506.
12. Carter, D. C., and J. X. Ho. 1994. Structure of serum albumin. Adv. Protein Chem. 45:153-203.
13. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
14. Cook, N. D. 1996. Scintillation proximity assay-a versatile high throughput screening technology. Drug Discov. Today 1:287-294.
15. Das, K., J. B. Bauman, A. D. Clark, Jr., Y. V. Frenkel, P. J. Lewi, A. J. Shatkin, S. H. Hughes, and E. Arnold. 2008. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U. S. A. 105:1466-1471.
16. de Béthune, M.-P., K. Hertogs, L. Heyndrickx, J. Vingerhoets, K. Fransen, H. Azijn, L. Michiels, W. Janssens, A. Scholliers, B. Larder, S. Bloor, R. Pauwels, and G. van der Groen. 1999. Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV 1 groups M (subtypes A-H) and [O], differ from subtype B? Antivir. Ther. 4(Suppl. 1):33.
17. de Béthune, M.-P., K. Andries, H. Azijn, J. Guillemont, J. Heeres, J. Vingerhoets, P. Lewi, E. Lee, P. Timmerman, and B. Williams. 2005. TMC278, a new potent NNRTI, with an increased barrier to resistance and favorable pharmacokinetic profile, abstr. 556. Abstr. 12th Conf. Retroviruses Opportunistic Infect. (CROI).
18. Delaugerre, C., R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, J. M. Huraux, C. Katlama, and V. Calvez. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 65:445-448.
19. EMEA. 2008. Summary of product characteristics for Intelence (etravirine) tablets. EMEA, London, England. http://www.emea.europa.eu/humandocs /Humans/EPAR/intelence/intelence.htm.
20. Fang, C., J. D. Bauman, K. Das, A. Remorino, E. Arnold, and R. M. Hochstrasser. 2008. Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 105:1472-1477.
21. Gazzard, B., E. J. Bernard, M. Boffito, D. Churchill, S. Edwards, N. Fisher, A. M. Geretti, M. Johnson, C. Leen, B. Peters, A. Pozniak, J. Ross, J. Walsh, E. Wilkins, and M. Youle. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 7:487-503.
22. Goebel, F., A. Yakovlev, A. H. Pozniak, E. Vinogradova, G. Boogaerts, R. Hoetelmans, M.-P. de Béthune, M. Peeters, and B. Woodfall. 2006. Shortterm antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 20:1721-1726.
23. Hertogs, K., M. P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
24. Jakubik, J. J., C. Chapron, L. Hubbard, M. Seifer, and D. N. Standring. 2008. In vitro cross-resistance profile for a next-generation NNRTI: IDX899, poster 26. Abstr. XVII Int. HIV Drug Resist. Workshop.
25. Janssen, P. A., P. J. Lewi, E. Arnold, F. Daeyaert, M. de Jonge, J. Heeres, L. Koymans, M. Vinkers, J. Guillemont, E. Pasquier, M. Kukla, D. Ludovici, K. Andries, M.-P. de Béthune, R. Pauwels, K. Das, A. D. Clark, Jr., Y. V. Frenkel, S. H. Hughes, B. Medaer, F. De Knaep, H. Bohets, F. De Clerck, A. Lampo, P. Williams, and P. Stoffels. 2005. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (R278474, rilpivirine). J. Med. Chem. 48:1901-1909.
26. Kaltenbach, J. P., M. H. Kaltenbach, and W. B. Lyons. 1958. Nigrosin as a dye for differentiating live and dead ascites cells. Exp. Cell Res. 15:112-117.
27. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
28. Larder, B., R. P. Harrigan, and K. Hertogs. November 2007. Establishment of biological cut-off values for predicting resistance to therapy. U.S. patent 7,292,944.
29. Lazzarin, A., T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall, on behalf of the DUET-2 study group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48.
30. Leitner, T., B. Korber, M. Daniels, C. Calef, and B. Foley. 2005. HIV-1 subtype and circulating recombinant form (CRF) reference sequences. Los Alamos National Laboratory, Los Alamos, NM. http://www.hiv.lanl.gov /content/sequence/HIV/COMPENDIUM/2005/RefSeqs05.pdf.
31. Lin, P. F., W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y. F. Gong, H. G. Wang, R. Rose, G. Yamanaka, B. Robinson, C. B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 100:11013-11018.
32. Madruga, J. V. R., I. Cassetti, A. Etzel, J. Suleiman, Y. Zhou, A. K. Cheng, and J. Enejosa. 2008. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviralnaïve patients through seven years, poster P004. Abstr. 9th Int. Cong. Drug Ther. HIV Infect.
33. Madruga, J. V., P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall, on behalf of the DUET-1 study group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a double-blind, placebo-controlled trial. Lancet 370:29-38.
34. Oie, S., M. A. Jacobson, and D. I. Abrams. 1993. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J. Acquir. Immune Defic. Syndr. 6:531-533.
35. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
36. Pelemans, H., A. Aertsen, K. Van Laethem, A. M. Vandamme, E. De Clercq, M. J. Pérez-Pérez, A. San-Félix, S. Velázquez, M. J. Camarasa, and J. Balzarini. 2001. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280:97-106.
37. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
38. Pozniak, A. L., J. Morales-Ramirez, E. Katabira, D. Steyn, S. H. Lupo, M. Santoscoy, B. Grinsztejn, K. Ruxrungtham, L. T. Rimsky, S. Vanveggel, and K. Boven. 2010. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 24:55-65.
39. Pozniak, A., J. Morales-Ramirez, L. Mohapi, M. Santoscoy, P. Chetchotisakd, M. Hereygers, S. Vanveggel, M. Peeters, B. Woodfall, and K. Boven. 2007. 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART naive patients, abstr. 144 LB. Abstr. 14th Conf. Retroviruses Opportunistic Infect.
40. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205.
41. Riddler, S. A., R. Haubrich, A. G. DiRienzo, L. Peeples, W. G. Powderly, K. L. Klingman, K. W. Garren, T. George, J. F. Rooney, B. Brizz, U. G. Lalloo, R. L. Murphy, S. Swindells, D. Havlir, and J. W. Mellors for the AIDS Clinical Trials Group Study A5142 Team. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:2095-2106.
42. Rimsky, L. T., L. Tambuyzer, J. Vingerhoets, H. Azijn, M. Staes, G. Picchio, G. Kraus, and M.-P. de Béthune. 2007. Compilation of mutations associated with resistance to NNRTIs deduced from clinical samples, in-vitro analyses, and bibliographical studies, abstr. 63. Abstr. XVI Int. HIV Drug Resist. Workshop.
43. Rosenkilde, M. M., L.-O. Gerlach, J. S. Jakobsen, R. T. Skerlj, G. J. Bridger, and T. W. Schwartz. 2004. Molecular mechanism of a AMD3100 antagonism in the CXCR4 receptor transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279:3033-3041.
44. Smith, T. F., and M. S. Waterman. 1981. Identification of common molecular subsequences. J. Mol. Biol. 147:195-197.
45. Sweeney, Z. K., and K. Klumpp. 2008. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr. Opin. Drug Discov. Devel. 11:458-470.
46. Tambuyzer, L., H. Azijn, L. T. Rimsky, J. Vingerhoets, P. Lecocq, G. Kraus, G. Picchio, and M. P. de Béthune. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 14:103-109.
47. Tibotec Pharmaceuticals, Ltd. 2008. Intelence product information. Tibotec Pharmaceuticals, Ltd., Mechelen, Belgium. http://www.intelence-info.com /intelence/assets/pdf/INTELENCE-PI.pdf.
48. Vermeiren, H., E. Van Craenenbroeck, P. Alen, L. Bacheler, G. Picchio, P. Lecocq, and the Virco Clinical Response Collaborative Team. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 145:47-55.
49. Vingerhoets, J., H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M.-P. de Béthune. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
50. Virco. 2009. Antivirogram phenotype report. Virco BVBA, Mechelen, Belgium. http://www.vircolab.com/product-center/antivirogram/the-antivirogram- report.
51. Vircolab. 2009. The virco® TYPE HIV-1 report. Virco BVBA, Mechelen, Belgium. http://www.vircolab.com/product-center/vircotype-hiv-1/the- vircotype-hiv-1-report.
52. Zhang, Z., R. Hamatake, and Z. Hong. 2004. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir. Chem. Chemother. 15:121-134.